Novo Nordisk A/S
I · Análisis con IA
En breve
Novo Nordisk develops and sells injectable and oral drugs primarily for diabetes and obesity, operating through two segments: Obesity and Diabetes Care (which includes cardiovascular treatments) and Rare Disease (covering blood disorders and hormone therapies) [Yahoo Finance]. The company also makes insulin delivery devices like smart pens and dose-tracking apps [Yahoo Finance]. Founded in 1923 and headquartered in Denmark, Novo Nordisk employs 67.900 people and sells its products globally across Europe, North America, Asia, and emerging markets [Yahoo Finance].
Novo Nordisk is a Danish pharmaceutical giant that makes diabetes and obesity drugs, most notably Wegovy and Ozempic (both forms of semaglutide) [Yahoo Finance]. The company is riding a massive wave of demand for GLP-1 weight-loss treatments, with recent trial data showing Wegovy works effectively in pill form and treats liver disease affecting one in three people with obesity [Yahoo Finance]. Despite strong financials and positive clinical momentum, the stock trades at a low 10,4x P/E ratio, which some analysts view as undervalued [Yahoo Finance].
Novo Nordisk is financially robust with exceptional margins, strong cash generation, and minimal debt burden [Yahoo Finance].
Puntuación Sentinellis
8,9/10
Financieramente sana
Capitalización bursátil
$196,2B
Ingresos (12 meses)
DKK 309,1B
Explicaciones
Cómo leemos estas cifras
Guías en lenguaje sencillo · sin cuenta
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
LeerPiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
LeerAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
LeerII · Noticias recientes
Qué movió el precio
6 noticias · ordenadas por relevancia
- Macro2026-05-20
How New Wegovy Obesity Trial Data At Novo Nordisk (CPSE:NOVO B) Has Changed Its Investment Story
Yahoo Finance
- Macro2026-05-18
3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now
Yahoo Finance
- Macro2026-05-19
Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide
Yahoo Finance
- Macro2026-05-19
Novo Nordisk Expands Parkinson's Bet With AI Partner And Upside Potential
Simply Wall St
- Macro2026-05-18
Novo Nordisk A/S - share repurchase programme
Yahoo Finance
- Macro2026-05-18
Novo Nordisk Eyes Global Push for Wegovy Pill
GuruFocus
Premium · gratis con cualquier cuenta
Novo Nordisk faces intense competition from Eli Lilly and other players developing GLP-1 drugs, with pressure mounting as rival therapies gain market share and compounding pharmacies produce cheaper alternatives [Yahoo Finance].
Riesgos
4
Oportunidades
7
Señales de alerta
2
Dirección
10
12 hallazgos más en el informe completo — gratis con cualquier cuenta.
Desbloquea el análisis completo de Novo Nordisk A/S
Crea una cuenta gratuita para acceder al informe completo generado con IA, con fuentes citadas en el texto.
- 4 riesgos, 7 oportunidades y 2 señales de alerta — cada uno con su fuente
- Más de 100 métricas financieras con gráficos y comparativas
- Resúmenes completos de noticias con enlaces a las fuentes
- Equipo directivo y remuneración
III · Empresas similares
También te puede interesar
Mismo sector · Salud — o salud financiera comparable
¿La añades a tu lista?